Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD200 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD200 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin controlled (<1.0 EU/μg). HEK293 expressed for native glycosylation. Sequence Verified. |
View CD200 Products |
| Gene Delivery | CD200 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based binding assays. |
View CD200 Products |
| Benchmark Ab | Anti-CD200 Recombinant Antibody Biosimilar based on Samalizumab sequence. Ideal positive control for blocking assays. |
View CD200 Products |
| Validator | CD200 siRNA Set Target-specific knockdown pool for specificity and functional validation. |
View CD200 Products |
| Related Target A | CD200R1 The primary inhibitory receptor for CD200. Essential for receptor-ligand blocking assays. |
View CD200R1 Products |
| Related Target B | CD47 Synergistic "don't eat me" signal. Dual-targeting of CD200 and CD47 enhances macrophage-mediated phagocytosis. |
View CD47 Products |
| Related Target C | PD-L1 Co-inhibitory pathway partner. Combined blockade of PD-L1 and CD200 overcomes adaptive immune resistance. |
View PD-L1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CD200-CD200R1 Interaction Blocking | HEK293-expressed CD200 and CD200R1 proteins preserve native post-translational modifications, ensuring accurate binding kinetics. |
| Cross-Species Cross-Reactivity | Human, Mouse, and Cynomolgus CD200 ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Lack of Validated Controls | Sequence-verified Samalizumab biosimilar antibody included as a benchmark positive control. |
| Off-Target Binding False Positives | Sequence-verified siRNA sets included for target knockdown and specificity verification in cell-based assays. |
Live CD200 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The CD200-CD200R1 pathway represents a highly potent "don't eat me" immune checkpoint, parallel to the CD47-SIRPα axis. CD200 is overexpressed on multiple myeloma, chronic lymphocytic leukemia (CLL), and various solid tumors, delivering inhibitory signals to myeloid cells and T cells. The race for CD200 therapeutics is intensifying, with major players shifting focus from traditional monotherapy mAbs to antibody-drug conjugates (ADCs) and bispecific platforms. As first-generation therapies reach the clinic, the next wave of R&D is targeting the synergistic blockade of CD200 alongside established checkpoints like PD-L1 or CD47 to overcome immunosuppressive tumor microenvironments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Blocking Monoclonal Antibody (mAb) | Alexion (AstraZeneca), Academic Institutions | CLL, Multiple Myeloma, Solid Tumors | Blocking Assay (Requires highly stable, native-conformation CD200R1 and CD200 ECD-Fc proteins) |
| Antibody-Drug Conjugate (ADC) | Biotech Startups | Small Cell Lung Cancer, Neuroendocrine Tumors | Internalization Assay (Requires HEK293-expressed CD200 for physiological endocytosis validation) |
| Bispecific / Multi-specific Antibodies | Oncology-focused Biopharma | Refractory Solid Tumors | Dual-Targeting Validation (Requires high-purity CD200 and partner antigens like PD-L1 or CD3) |